Ana Zurisadai Gonzalez Buenrostro

USPTO Granted Patents = 19 (Patent Applications = 12)

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 14 (Patent Applications = 19)

Average Co-Inventor Count = 13.0

ph-index = 6

Forward Citations = 83(Granted Patents)

Company Filing History:

11 out of 924

Gilead Sciences, Inc.

Years Active: 2016-2025

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12227520 - Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use (2025-02-18),

2. 12187734 - Substituted pyridotriazine compounds and uses thereof (2025-01-07),

3. 12054496 - Bridged tricyclic carbamoylpyridone compounds and uses thereof (2024-08-06),

4. 12024528 - Bridged tricyclic carbamoylpyridone compounds and uses thereof (2024-07-02),

5. 11897892 - Substituted pyridotriazine compounds and uses thereof (2024-02-13),

6. 11613546 - Substituted pyridotriazine compounds and uses thereof (2023-03-28),

7. 11548902 - Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use (2023-01-10),

8. 11352371 - Thienopyrimidine derivatives as ACC inhibitors and uses thereof (2022-06-07),

9. 11352329 - HIV protease inhibitors (2022-06-07),

10. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

11. 11274105 - Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists (2022-03-15),

12. 11084832 - Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use (2021-08-10),

13. 10836779 - Compounds that inhibit MCL-1 protein (2020-11-17),

14. 10774053 - HIV protease inhibitors (2020-09-15),

15. 10100063 - Compounds that inhibit Mcl-1 protein (2018-10-16),

Title: Ana Zurisadai Gonzalez Buenrostro: A Pioneer in HIV Treatment Innovations

Introduction:

Ana Zurisadai Gonzalez Buenrostro is a standout inventor based in San Mateo, CA, with a remarkable portfolio of 14 patents to her name. Her groundbreaking work in pharmaceutical compounds has made significant strides in the field of treating and preventing human immunodeficiency virus (HIV) infections.

Latest Patents:

1. Substituted pyridotriazine compounds and uses thereof: Ana's innovative compounds show promise in combating HIV infections through advanced pharmaceutical compositions and methods of production.

2. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use: Her patented compounds, designed for treating HIV, have opened new avenues in the quest for effective treatments against the virus.

Career Highlights:

Ana Gonzalez Buenrostro is a valued member of Gilead Sciences, Inc., a renowned pharmaceutical company leading the way in HIV treatment research and development. Her contributions have been instrumental in the company's success in developing cutting-edge treatments for HIV.

Collaborations:

Ana has worked closely with esteemed colleagues Zhihong Li and Julio Cesar Medina at Gilead Sciences, Inc., pooling their expertise and skills to drive forward innovative solutions in the fight against HIV.

Conclusion:

In conclusion, Ana Zurisadai Gonzalez Buenrostro's dedication to pioneering advancements in HIV treatment through her patented compounds is truly commendable. Her collaborative efforts with colleagues at Gilead Sciences, Inc., continue to shape the landscape of pharmaceutical innovations aimed at combating HIV infections.

This text is generated by artificial intelligence and may not be accurate.